newsfilter
← Earnings
Earnings Releases·

Prothena Corporation — Third Quarter 2026 Earnings Summary

Prothena Corporation reported a net loss of $16.5 million for the third quarter of 2026 and $2.4 million for the first nine months, while total revenue reached $0.6 million and $52.7 million respectively. The company's cash position stood at $272.2 million as of September 30, 2026, with no debt outstanding. Clinical updates highlighted a decrease in the inflammatory biomarker hsCRP for coramitug in ATTR-CM patients and ongoing Phase 3 trials for prasinezumab and coramitug expected to complete in 2029. Additionally, Bristol Myers Squibb continues evaluating moponetug for Alzheimer's disease with data readout anticipated in the first half of 2027.

Company
PROTHENA CORP PUBLIC LTD CO
Sector
Healthcare
Industry
Biotechnology